-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Glioblastoma -X- _ B-Patient
is -X- _ O
the -X- _ O
most -X- _ O
frequent -X- _ O
and -X- _ O
most -X- _ O
malignant -X- _ O
primary -X- _ O
brain -X- _ O
tumor -X- _ O
with -X- _ O
a -X- _ O
poor -X- _ O
prognosis. -X- _ O
The -X- _ O
translation -X- _ O
of -X- _ O
therapeutic -X- _ O
strategies -X- _ O
for -X- _ O
glioblastoma -X- _ O
from -X- _ O
the -X- _ O
experimental -X- _ O
phase -X- _ O
into -X- _ O
the -X- _ O
clinic -X- _ O
has -X- _ O
been -X- _ O
limited -X- _ O
by -X- _ O
insufficient -X- _ O
animal -X- _ O
models -X- _ O
, -X- _ O
which -X- _ O
lack -X- _ O
important -X- _ O
features -X- _ O
of -X- _ O
human -X- _ O
tumors. -X- _ O
Lentiviral -X- _ B-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
is -X- _ O
an -X- _ O
attractive -X- _ O
therapeutic -X- _ O
option -X- _ O
for -X- _ O
human -X- _ O
glioblastoma -X- _ O
, -X- _ O
which -X- _ O
we -X- _ O
validated -X- _ O
in -X- _ O
a -X- _ O
clinically -X- _ O
relevant -X- _ O
animal -X- _ O
model. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
We -X- _ O
used -X- _ O
a -X- _ O
rodent -X- _ B-Patient
xenograft -X- _ I-Patient
model -X- _ I-Patient
that -X- _ O
recapitulates -X- _ O
the -X- _ O
invasive -X- _ O
and -X- _ O
angiogenic -X- _ O
features -X- _ O
of -X- _ O
human -X- _ B-Patient
glioblastoma -X- _ I-Patient
to -X- _ O
analyze -X- _ O
the -X- _ O
transduction -X- _ O
pattern -X- _ O
and -X- _ O
therapeutic -X- _ O
efficacy -X- _ O
of -X- _ O
lentiviral -X- _ O
pseudotyped -X- _ O
vectors. -X- _ O
Both -X- _ O
, -X- _ O
lymphocytic -X- _ B-Intervention
choriomeningitis -X- _ I-Intervention
virus -X- _ I-Intervention
glycoprotein -X- _ I-Intervention
( -X- _ I-Intervention
LCMV-GP -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
vesicular -X- _ I-Intervention
stomatitis -X- _ I-Intervention
virus -X- _ I-Intervention
glycoprotein -X- _ I-Intervention
( -X- _ I-Intervention
VSV-G -X- _ I-Intervention
) -X- _ I-Intervention
pseudotyped -X- _ I-Intervention
lentiviral -X- _ I-Intervention
vectors -X- _ I-Intervention
very -X- _ O
efficiently -X- _ B-Outcome
transduced -X- _ I-Outcome
human -X- _ I-Outcome
glioblastoma -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo. -X- _ I-Outcome
In -X- _ O
contrast -X- _ O
, -X- _ O
pseudotyped -X- _ B-Outcome
gammaretroviral -X- _ I-Outcome
vectors -X- _ I-Outcome
, -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
evaluated -X- _ I-Outcome
for -X- _ I-Outcome
clinical -X- _ I-Outcome
therapy -X- _ I-Outcome
of -X- _ I-Outcome
glioblastoma -X- _ I-Outcome
, -X- _ I-Outcome
showed -X- _ I-Outcome
inefficient -X- _ I-Outcome
gene -X- _ I-Outcome
transfer -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo. -X- _ I-Outcome
Both -X- _ O
pseudotyped -X- _ O
lentiviral -X- _ O
vectors -X- _ O
transduced -X- _ O
cancer -X- _ O
stem-like -X- _ O
cells -X- _ O
characterized -X- _ O
by -X- _ O
their -X- _ O
CD133- -X- _ O
, -X- _ O
nestin- -X- _ O
and -X- _ O
SOX2-expression -X- _ O
, -X- _ O
the -X- _ O
ability -X- _ O
to -X- _ O
form -X- _ O
spheroids -X- _ O
in -X- _ O
neural -X- _ O
stem -X- _ O
cell -X- _ O
medium -X- _ O
and -X- _ O
to -X- _ O
express -X- _ O
astrocytic -X- _ O
and -X- _ O
neuronal -X- _ O
differentiation -X- _ O
markers -X- _ O
under -X- _ O
serum -X- _ O
conditions. -X- _ O
In -X- _ O
a -X- _ O
therapeutic -X- _ O
approach -X- _ O
using -X- _ O
the -X- _ O
suicide -X- _ O
gene -X- _ O
herpes -X- _ O
simplex -X- _ O
virus -X- _ O
thymidine -X- _ O
kinase -X- _ O
( -X- _ O
HSV-1-tk -X- _ O
) -X- _ O
fused -X- _ O
to -X- _ O
eGFP -X- _ O
, -X- _ O
both -X- _ B-Outcome
lentiviral -X- _ I-Outcome
vectors -X- _ I-Outcome
mediated -X- _ I-Outcome
a -X- _ I-Outcome
complete -X- _ I-Outcome
remission -X- _ I-Outcome
of -X- _ I-Outcome
solid -X- _ I-Outcome
tumors -X- _ I-Outcome
as -X- _ I-Outcome
seen -X- _ I-Outcome
on -X- _ I-Outcome
MRI -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
highly -X- _ I-Outcome
significant -X- _ I-Outcome
survival -X- _ I-Outcome
benefit -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.001 -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
control -X- _ I-Outcome
groups. -X- _ I-Outcome
In -X- _ O
all -X- _ O
recurrent -X- _ O
tumors -X- _ O
, -X- _ O
surviving -X- _ O
eGFP-positive -X- _ O
tumor -X- _ O
cells -X- _ O
were -X- _ O
found -X- _ O
, -X- _ O
advocating -X- _ O
prodrug -X- _ O
application -X- _ O
for -X- _ O
several -X- _ O
cycles -X- _ O
to -X- _ O
even -X- _ O
enhance -X- _ O
and -X- _ O
prolong -X- _ O
the -X- _ O
therapeutic -X- _ O
effect. -X- _ O
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
In -X- _ O
conclusion -X- _ O
, -X- _ O
lentiviral -X- _ B-Intervention
pseudotyped -X- _ I-Intervention
vectors -X- _ I-Intervention
are -X- _ O
promising -X- _ B-Outcome
candidates -X- _ I-Outcome
for -X- _ I-Outcome
gene -X- _ I-Outcome
therapy -X- _ I-Outcome
of -X- _ I-Outcome
glioma -X- _ I-Outcome
in -X- _ I-Outcome
patients. -X- _ I-Outcome
The -X- _ O
inefficient -X- _ O
gene -X- _ O
delivery -X- _ O
by -X- _ O
gammaretroviral -X- _ O
vectors -X- _ O
is -X- _ O
in -X- _ O
line -X- _ O
with -X- _ O
the -X- _ O
results -X- _ O
obtained -X- _ O
in -X- _ O
clinical -X- _ O
therapy -X- _ O
for -X- _ O
GBM -X- _ O
and -X- _ O
thus -X- _ O
confirms -X- _ O
the -X- _ O
high -X- _ O
reproducibility -X- _ O
of -X- _ O
the -X- _ O
invasive -X- _ O
glioma -X- _ O
animal -X- _ O
model -X- _ O
for -X- _ O
translational -X- _ O
research -X- _ O
. -X- _ O

